Aprecia 3D Printing in Medicine
A BROAD SPECTRUM OF NEW PRODUCT POSSIBILITIES. As the global leader of 3D printing in medicine, we give our partners the ability to develop formulations beyond the limitations of compression method tableting, bringing you and the patients you serve substantial benefits today.
Actived: 4 days ago
Technology 3D Printed Drugs Aprecia
(4 days ago) Using an aqueous fluid to bind together multiple layers of powder, our unique, patent-protected 3DP technology platform can be used to solve some of your toughest product formulation challenges across multiple therapeutic areas. Oral medications can pose administration and/or swallowing challenges for patients in a broad range of disease areas.
Practical Applications for 3DP Drug Manufacturing: Today and
(7 days ago) The emergence of 3DP for Pharma is a significant industry advancement, as it will ultimately revolutionize the way we manufacture drugs in the digital age. The pharmaceutical industry can benefit from Aprecia’s ZipDose technology, the world’s first and only FDA-validated, commercial-scale 3DP for pharma.
FDA Approves The First 3d Printed Drug Product
(5 days ago) BLUE ASH, Ohio, August 3, 2015 – Aprecia Pharmaceuticals Company today announced that the U.S. Food and Drug Administration (FDA) has approved SPRITAM® levetiracetam for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and
New Chemical Entity NCE Formulation Advantages Aprecia
(3 days ago) Aprecia’s unique technology unlocks 3DP dosage forms with unique advantages – giving you new power to make sure your NCE reaches its full therapeutic and market potential. Developing novel 3DP dosage forms with Aprecia can help you solve formulation challenges through: Patent-protected technology for oral dispersible dosage strengths above
Lifecycle Management Aprecia
(4 days ago) SVP, Business Development, Aprecia. “Pharmaceutical companies and their drugs face numerous challenges in the brief window between launch and patent expiration which make it important to plan lifecycle management (LCM) strategies well in advance of patent expiry. For pharmaceutical companies that seek market enhancements strategies beyond the
First FDA-Approved Medicine Manufactured Using 3d Printing
(2 days ago) SPRITAM is the first prescription drug product approved by the U.S. Food and Drug Administration (FDA) that is manufactured using 3D printing technology. This innovative product disintegrates in the mouth with a sip of liquid and offers a new option for patients, including those who may struggle to take their medicine.
ZipDose Technology Spritam Aprecia
(2 days ago) Manufactured with Aprecia’s ZipDose 3DP technology, Spritam (levetiracetam) is available in 4 dose strengths, up to 1,000 mg, and provides appropriate patients who may have difficulty swallowing large tablets an option for an advanced fast-melt tablet. Spritam is the first 3D printed drug approved by the FDA and is currently available by
Aprecia and CMIC, a Leading CDMO in Japan, have established an
(5 days ago) Also, the company operates to respond to diversifying needs by managing the Health care Business sector and developing and selling diagnostic pharmaceuticals andorphan drugs. CMIC Group has developed a unique business model called Pharmaceutical Value Creator (PVC) based on its abundant accumulated experience and knowledge as a CRO pioneer.
About Us 3DP Aprecia
(9 days ago) about us. THE FUTURE OF PHARMACEUTICAL MANUFACTURING IS HAPPENING HERE. Aprecia is the global leader in commercial-scale 3DP for pharmaceutical manufacturing technology. We’re committed to creating new solutions for unmet healthcare needs by developing pharma-ready innovations and complementary technology platforms that enable patient-centric
Estimating the Incremental Burden of Dysphagia in Epilepsy
(6 days ago) The successful treatment of epilepsy with antiepileptic drugs (AEDs) can depend on the patient’s adherence to medication and literature has shown that non-adherence, often affected by dysphagia, is a significant issue in this population. This study estimated the annual incremental healthcare burden of dysphagia in individuals with epilepsy
Aprecia Hires Lynda Harker to Lead National Sales Team
(3 days ago) Harker and Aprecia's national sales team will be poised to launch renewed promotional efforts of SPRITAM in October 2019. "Lynda is a top performer with both clinical and commercial pharmaceutical expertise," said Chris Gilmore, Aprecia's Chief Executive Officer. "Her sales leadership roles in specialty and primary care at both Eli Lilly and
Careers Pharma Manufacturing Jobs Aprecia
(7 days ago) Careers. JOIN THE LEADER IN 3D PRINTED PHARMACEUTICALS. The future of pharmaceuticals manufacturing is happening at Aprecia, and we want you to join us. At Aprecia, team members are committed to L E A D: leadership, excellence, awareness and determination. These core values are what keep us motivated and accountable to the next generation of